An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)

被引：2
|
作者：
Dimopoulos, Meletios [1 ]
Grosicki, Sebastian [2 ]
Jedrzejczak, Wieslaw [3 ]
Nahi, Hareth [4 ]
Gruber, Astrid [4 ]
Hansson, Markus [5 ]
Byrne, Catriona [6 ]
Labotka, Richard [6 ]
Teng, Zhaoyang [6 ]
Yang, Huyuan [6 ]
Grzasko, Norbert [7 ,8 ]
Kumar, Shaji [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Silesian Med Univ Katowice, Katowice, Poland
[3] Med Univ Warsaw, Warsaw, Poland
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Skane Univ Hosp, Lund, Sweden
[6] Millennium Pharmaceut Inc, Cambridge, MA USA
[7] Med Univ Lublin, Lublin, Poland
[8] St Johns Canc Ctr, Lublin, Poland
[9] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MM-135
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [1] AN OPEN-LABEL, PHASE 2 STUDY TO EVALUATE THE ORAL COMBINATION OF IXAZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Grosicki, S.
    Jedrzejczak, W.
    Nahi, H.
    Gruber, A.
    Hansson, M.
    Byrne, C.
    Labotka, R.
    Teng, Z.
    Yang, H.
    Grzasko, N.
    Kumar, S.
    HAEMATOLOGICA, 2017, 102 : 111 - 111
  • [2] All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Dimopoulos, Meletios A.
    Grosicki, Sebastian
    Jedrzejczak, Wieslaw W.
    Nahi, Hareth
    Gruber, Astrid
    Hansson, Markus
    Gupta, Neeraj
    Byrne, Catriona
    Labotka, Richard
    Teng, Zhaoyang
    Yang, Huyuan
    Grzasko, Norbert
    Kumar, Shaji
    EUROPEAN JOURNAL OF CANCER, 2019, 106 : 89 - 98
  • [3] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    BLOOD, 2021, 137 (26) : 3616 - 3628
  • [4] Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma
    Yan Wang
    Yuan-Fang Liu
    Shi-Wei Jin
    Yi Tao
    Wei-Ping Zhang
    Jian-Lin Chen
    Song-Fu Jiang
    Jian-Qing Mi
    Scientific Reports, 15 (1)
  • [5] Phase 1/2 trial of ixazomib, cyclophosphamide, and dexamethasone for newly diagnosed multiple myeloma (NDMM).
    Lacy, Martha
    Bergsagel, P. Leif
    LaPlant, Betsy
    Halvorson, Alese
    Buadi, Francis
    Leung, Nelson
    Go, Ronald S.
    Dingli, David
    Kapoor, Prashant
    Gertz, Morie A.
    Lin, Yi
    Dispenzieri, Angela
    Hwa, Yi Lisa
    Fonder, Amie
    Fonseca, Rafael
    Hayman, Suzanne R.
    Stewart, A. Keith
    Mikhael, Joseph
    Rajkumar, S. Vincent
    Kumar, Shaji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
    Ocio, Enrique M. M.
    Bringhen, Sara
    Martinez-Lopez, Joaquin
    San-Miguel, Jesus
    Oliva, Stefania
    Rodriguez-Otero, Paula
    Le Roux, Nadia
    Dong, Yvonne
    Doroumian, Severine
    Mace, Sandrine
    Mateos, Maria-Victoria
    HEMASPHERE, 2023, 7 (02):
  • [7] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    Bringhen, S.
    D'Agostino, M.
    De Paoli, L.
    Montefusco, V.
    Liberati, A. M.
    Galieni, P.
    Grammatico, S.
    Muccio, V. E.
    Esma, F.
    De Angelis, C.
    Musto, P.
    Ballanti, S.
    Offidani, M.
    Petrucci, M. T.
    Gaidano, G.
    Corradini, P.
    Palumbo, A.
    Sonneveld, P.
    Boccadoro, M.
    LEUKEMIA, 2018, 32 (04) : 979 - 985
  • [8] Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)
    Dimopoulos, Meletios A.
    Grosicki, Sebastian
    Jedrzejczak, Wieslaw W.
    Nahi, Hareth
    Gruber, Astrid
    Hansson, Markus
    Byrne, Catriona
    Labotka, Richard
    Hui, Ai-Min
    Teng, Zhaoyang
    Grzasko, Norbert
    BLOOD, 2015, 126 (23)
  • [9] Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma
    S Bringhen
    M D'Agostino
    L De Paoli
    V Montefusco
    A M Liberati
    P Galieni
    S Grammatico
    V E Muccio
    F Esma
    C De Angelis
    P Musto
    S Ballanti
    M Offidani
    M T Petrucci
    G Gaidano
    P Corradini
    A Palumbo
    P Sonneveld
    M Boccadoro
    Leukemia, 2018, 32 : 979 - 985
  • [10] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
    O'Donnell, Elizabeth K.
    Suman, Vera Jean
    Geyer, Susan M.
    Nadeem, Omar
    Dinner, Shira
    Yee, Andrew J.
    Laubach, Jacob P.
    Mo, Clifton C.
    Tuchman, Sascha A.
    Donadio, Kristen
    Sinclair, Sarah
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
12345